Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285012 · ClinicalTrials.gov registry record · Phase 3
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
A Phase 3 study of Smoking Cessation, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
- 20
- Study locations
NCT00285012: Completed Phase 3 study of Smoking Cessation, sponsored by Pfizer.
NCT00285012 is a Phase 3 study of Smoking Cessation that has completed, run by Pfizer. The registered enrollment target is 504 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00285012, a Phase 3 study of Smoking Cessation, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
Primary Outcome
Number of subjects who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory \[NUI\]) and with end-expiratory exhaled carbon monoxide (CO) measurement less than or equal to 10 parts per million (ppm) for weeks 9 through 12 (inclusive).
Conditions Studied
Interventions
- DRUG placebo
- DRUG Varenicline Tartarate
Study Locations (20)
North Carolina
- Pfizer Investigational Site - Chapel Hill
- Pfizer Investigational Site - Chapel Hill
- Pfizer Investigational Site - Raleigh
- Pfizer Investigational Site - Winston-Salem
- Pfizer Investigational Site - Winston-Salem
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
Connecticut
- Pfizer Investigational Site - Farmington
- Pfizer Investigational Site - Farmington
Alabama
- Pfizer Investigational Site - Birmingham
Colorado
- Pfizer Investigational Site - Denver
Florida
- Pfizer Investigational Site - Miami
Kentucky
- Pfizer Investigational Site - Lexington
Maine
- Pfizer Investigational Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00285012 record still lists
NCT00285012 is an interventional study that assigns participants to a tested intervention. The registered 504 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00285012 names 20 study sites across 14 states, led by North Carolina, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00285012 about?
NCT00285012 is a clinical study titled "Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).". This study is to be conducted in subjects with mild-to-moderate COPD who are cigarette smokers with the intent of demonstrating differences in smoking cessation between varenicline and placebo.
What is the current status of trial NCT00285012?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2006-05. Estimated completion is 2009-04.
What conditions does trial NCT00285012 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT00285012?
The interventions under investigation include: placebo (DRUG), Varenicline Tartarate (DRUG).
Who is sponsoring clinical trial NCT00285012?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00285012 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00285012's enrollment target sits among peer trials
504 52nd of 188 higher than 137 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
-
Nicotine Mouth Film for Craving Relief.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- NCT06736522 · 504 participants · NA
Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program
- NCT06822257 · 504 participants · NA
Drinking in Young Adult Duos (DYAD) Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia